On Thursday, the U.S. Senate passed (85-7) the fiscal year 2019 minibus appropriations bill (H.R.6157) that would fund the Departments of Labor, Health and Human Services (HHS), and Education, attaching to it a large amendment package. The bill includes S.Amdt. 3964, an amendment introduced by Sens. Richard Durbin (D-IL) and Chuck Grassley (R-IA) that provides
Adoption of value-based pricing, where drug prices are linked to real-world outcomes rather than on a per-pill or per-treatment basis, will have a profound impact on the pharmaceutical industry.
At the instruction of Prime Minister Shinzo Abe, Japan’s Council on Economic and Fiscal Policy has begun to draw up a basic policy on drug pricing, based on which the Japanese government will start to reform the country’s prescription drug pricing system.
Turing Pharmaceuticals CEO Martin Shkreli and his notorious $750 pill have brought new media attention and public outcry to the already contentious issue of drug pricing. But Beth Roberts, partner in the health group at Hogan Lovells, argues that while profiteering stories get the bulk of the attention, the issue of drug pricing is much more complex.